2023
Using the exploration, preparation, implementation, sustainment (EPIS) framework to assess the cooperative re-engagement controlled trial (CoRECT)
Elder H, Lang S, Villanueva M, John B, Roosevelt K, Altice F, Brady K, Gibson B, Buchelli M, DeMaria A, Randall L. Using the exploration, preparation, implementation, sustainment (EPIS) framework to assess the cooperative re-engagement controlled trial (CoRECT). Frontiers In Public Health 2023, 11: 1223149. PMID: 38106893, PMCID: PMC10722986, DOI: 10.3389/fpubh.2023.1223149.Peer-Reviewed Original ResearchMeSH KeywordsHIV InfectionsHumansMassachusettsPublic HealthRandomized Controlled Trials as TopicResearch DesignRetrospective StudiesConceptsPublic health surveillance dataHealth surveillance dataHIV careSurveillance dataHealth department jurisdictionsPublic health practicePublic health agenciesStudy protocolClinic dataClinic partnersCase identificationHealth practicesHealth agenciesIntervention design processTrial sitesIntervention developmentTrialsCareInterventionSustainment (EPIS) frameworkEPIS frameworkIterative discussionsStaff capacityCommunity partnersRe-EngagementExpanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach?
Hao R, Brooks R, Zelenev A, Spinner G, Barakat L, Villanueva M. Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach? Health Promotion Practice 2023, 24: 1009-1017. PMID: 37439817, DOI: 10.1177/15248399231169794.Peer-Reviewed Original ResearchConceptsHepatitis C virusRisk factor-based screeningElectronic medical recordsHIV clinicAnnual screeningC virusRisk factorsScreening siteAnnual screening ratesNew HCV diagnosesClinical decision support toolRisk factor assessmentPublic health expertsHCV testingHCV casesClinical decision supportHCV diagnosisHCV testScreening ratesProspective studyMedical recordsPositivity ratePositive casesUnprotected sexClinicImproving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchMeSH KeywordsCoinfectionHepacivirusHepatitis CHIV InfectionsHumansOpiate AlkaloidsSubstance-Related DisordersConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centersCreating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods
Brooks R, Wegener M, Speers S, Nichols L, Sideleau R, Valeriano T, Buchelli M, Villanueva M. Creating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods. Health Promotion Practice 2023, 24: 1039-1049. PMID: 37439600, DOI: 10.1177/15248399231169792.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCoinfectionFemaleHepacivirusHepatitis CHepatitis C, ChronicHIV InfectionsHumansMaleConceptsHIV/HCV coinfectionHCV coinfectionHepatitis C virusSVR ratesHCV treatmentHIV clinicTreatment cascadeTreatment statusSustained virologic response ratesHCV care cascadeHCV treatment cascadeHCV treatment statusVirologic response ratesHIV viral suppressionPatient treatment statusPublic health approachCare cascadeHepatitis CViral suppressionActing antiviralsTreatment initiationC virusResponse rateClinical staffCoinfectionFuture Directions for HIV/HCV Care: Lessons Learned From Local Evaluation Projects in Texas and Connecticut and Implications for Practice and Health Promotion
Villanueva M. Future Directions for HIV/HCV Care: Lessons Learned From Local Evaluation Projects in Texas and Connecticut and Implications for Practice and Health Promotion. Health Promotion Practice 2023, 24: 1050-1054. PMID: 37439561, DOI: 10.1177/15248399231169919.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsConnecticutHealth PromotionHepacivirusHepatitis CHIV InfectionsHumansTexasConceptsServices Administration's Special ProjectsHCV elimination goalsSystem-level barriersHCV careHCV cureHepatitis CElimination goalsHealth promotionYale University SchoolIndividualized approachPriority populationsLocal implementation strategiesLevel barriersUniversity SchoolImplementation strategiesHCVHIVPatientsSan AntonioEvaluation projectCareCharacterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels
Zhao A, Wegener M, Brooks R, Mininberg L, Helou E, Maughan A, Villanueva M. Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels. Health Promotion Practice 2023, 24: 1029-1038. PMID: 37439687, DOI: 10.1177/15248399231169793.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHepatitis C virusHCV coinfectionHIV clinicDirect-acting antiviral medicationsHIV transmission risk factorsPrimary care HIV clinicClinic-level barriersHCV elimination targetsChronic HCV infectionRetrospective chart reviewPatient-level barriersClinical practice patternsMedication-assisted treatmentTransmission risk factorsIllicit substance usePatient-specific issuesLack of transportationSubstance use problemsMental health issuesHCV cureHCV infectionHCV treatmentHepatitis CUntreated patientsChallenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias
DiDomizio E, Chandra D, Nichols L, Villanueva M, Altice F. Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias. Health Promotion Practice 2023, 24: 998-1008. PMID: 37440258, DOI: 10.1177/15248399231169928.Peer-Reviewed Original ResearchMeSH KeywordsBias, ImplicitDrug UsersHepacivirusHepatitis CHIV InfectionsHumansSubstance Abuse, IntravenousUnited StatesConceptsNominal group techniqueHealth care decisionsProvider perspectivesEligibility criteriaHIV/HCVEffective antiviral medicationsPatient eligibility criteriaFacilitators of treatmentMicro-EliminationHCV treatmentAntiviral medicationsOpioid epidemicProvider knowledgePatient involvementPatient engagementDifferent clinicsRelated stigmaHCVCare decisionsHIVPatientsTreatmentGroup sessionsMost barriersFocus group sessionsThe Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment
O'Shea J, Fanfair R, Williams T, Khalil G, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 93: 134-142. PMID: 36812382, PMCID: PMC10962216, DOI: 10.1097/qai.0000000000003178.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsFemaleHIV InfectionsHumansMassachusettsParturitionPregnancyProspective StudiesViral LoadConceptsDurable viral suppressionActive public health interventionProportion of PWHPublic health interventionsViral loadCare strategiesHealth interventionsLast viral loadCopies/mLStandard of careRace/ethnicityCare armHIV careViral suppressionAntiretroviral adherenceCD4 categoryExposure categoriesCare individualsPWHCareAge categoriesInterventionTrialsBirth sexRe-EngagementCosts and cost‐effectiveness of a collaborative data‐to‐care intervention for HIV treatment and care in the United States
Shrestha R, Fanfair R, Randall L, Lucas C, Nichols L, Camp N, Brady K, Jenkins H, Altice F, DeMaria A, Villanueva M, Weidle P. Costs and cost‐effectiveness of a collaborative data‐to‐care intervention for HIV treatment and care in the United States. Journal Of The International AIDS Society 2023, 26: e26040. PMID: 36682053, PMCID: PMC9867888, DOI: 10.1002/jia2.26040.Peer-Reviewed Original ResearchConceptsCare armHIV careCare patientsIntervention armCare interventionsHealth departmentsHIV care interventionsHIV care outcomesHIV care providersHealthcare provider perspectiveHIV clinicHIV treatmentCare providersControl trialCare outcomesMicrocosting approachCare programCare servicesSurveillance dataSimilar interventionsIncremental costIntervention costsProvider perspectivesCareAverage cost
2022
Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
Brothers S, DiDomizio E, Nichols L, Brooks R, Villanueva M. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. AIDS And Behavior 2022, 27: 119-133. PMID: 35776253, PMCID: PMC9663279, DOI: 10.1007/s10461-022-03749-8.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCoinfectionHepacivirusHepatitis CHepatitis C, ChronicHIV InfectionsHumansUnited StatesConceptsDirect acting antiviralsHIV/HCVDAA treatmentHCV treatmentHIV/HCV Co-infectionDAA treatment uptakeHCV Co-InfectionPatient-level barriersHCV diseaseAdherence supportHepatitis CActing antiviralsTreatment uptakeCo-InfectionTreatment barriersHCVTreatmentPWHAntiviralsQualitative interviewsHIVDiseaseDiagnosisPersonsUptakeAdvancing data to care strategies for persons with HIV using an innovative reconciliation process
Villanueva M, Miceli J, Speers S, Nichols L, Carroll C, Jenkins H, Altice F. Advancing data to care strategies for persons with HIV using an innovative reconciliation process. PLOS ONE 2022, 17: e0267903. PMID: 35511958, PMCID: PMC9071117, DOI: 10.1371/journal.pone.0267903.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory Care FacilitiesContinuity of Patient CareHIV InfectionsHumansMiddle AgedPublic Health SurveillanceViral LoadConceptsDisease intervention specialistsHIV care continuumCare continuumNon-randomized patientsPublic health surveillance dataOngoing HIV transmissionClinic visit dataHealth surveillance dataPublic health surveillanceHIV clinicHIV eliminationViral loadHIV transmissionCare engagementCopies/Clinic staffClinic dataYale University SchoolVisit dataHealth surveillancePWHSurveillance dataPatientsCells/Intervention specialistsExperiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study
Harsono D, Deng Y, Chung S, Barakat LA, Friedland G, Meyer JP, Porter E, Villanueva M, Wolf MS, Yager JE, Edelman EJ. Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study. AIDS And Behavior 2022, 26: 2099-2111. PMID: 35064390, PMCID: PMC8782707, DOI: 10.1007/s10461-021-03556-7.Peer-Reviewed Original ResearchConceptsHIV careRe-engage patientsMixed-methods studyCare team membersRoutine clinical experienceCOVID-19 pandemicBenefits of telemedicineHIV clinicTelemedicine visitsTelemedicine appointmentsReimbursement concernsClinical experienceClinical staffCareAppropriate billingPatientsPWHTelemedicinePatient remote monitoringReimbursement methodsPandemicHIVClinicVisits
2021
Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study
Virata MD, Shenoi SV, Ladines-Lim J, Villanueva MS, Barakat LA. Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study. PLOS ONE 2021, 16: e0260251. PMID: 34851963, PMCID: PMC8635326, DOI: 10.1371/journal.pone.0260251.Peer-Reviewed Original ResearchConceptsOne-year retrospective cohort studyCohort of PWHNon-communicable comorbiditiesPredictors of hospitalizationRetrospective cohort studyChronic lung diseaseLikelihood of hospitalizationSingle-site experienceCOVID-19 infectionNon-communicable diseasesOutcomes of peopleCohort studyHIV diseaseOverall mortalityClinical outcomesLung diseaseCardiovascular diseaseHospitalizationCumulative burdenHIVLater timeframeDiseaseEarly epidemicPWHOutcomesNational Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States
Werbel WA, Brown DM, Kusemiju OT, Doby BL, Seaman SM, Redd AD, Eby Y, Fernandez RE, Desai NM, Miller J, Bismut GA, Kirby CS, Schmidt HA, Clarke WA, Seisa M, Petropoulos CJ, Quinn TC, Florman SS, Huprikar S, Rana MM, Friedman-Moraco RJ, Mehta AK, Stock PG, Price JC, Stosor V, Mehta SG, Gilbert AJ, Elias N, Morris MI, Mehta SA, Small CB, Haidar G, Malinis M, Husson JS, Pereira MR, Gupta G, Hand J, Kirchner VA, Agarwal A, Aslam S, Blumberg EA, Wolfe CR, Myer K, Wood RP, Neidlinger N, Strell S, Shuck M, Wilkins H, Wadsworth M, Motter JD, Odim J, Segev DL, Durand CM, Tobian AAR, Piquant D, Link K, Hemmersbach-Miller M, Pearson T, Turgeon N, Lyon G, Kitchens W, Huckaby J, Lasseter A, Elbein R, Roberson A, Ferry E, Klock E, Cochran W, Morrison M, Rasmussen S, Bollinger J, Sugarman J, Smith A, Thomas M, Coakley M, Timpone J, Stucke A, Haydel B, Dieter R, Klein E, Neumann H, Gallon L, Goudy L, Callegari M, Marrazzo I, Jackson T, Pruett T, Farnsworth M, Locke J, Mompoint-Williams D, Basinger K, Mekeel K, Nguyen P, Kwan J, Srisengfa T, Chin-Hong P, Rogers R, Simkins J, Munoz C, Dunn T, Sawinski D, Silveira F, Hughes K, Pakstis D, Nagy J, Baldecchi M, Muthukumar T, Eddie M, Robb K, Salsgiver E, Witting B, Azar M, Villanueva M, Formica R, Tomlin R. National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States. Clinical Infectious Diseases 2021, 74: 2010-2019. PMID: 34453519, PMCID: PMC9187316, DOI: 10.1093/cid/ciab743.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug resistance mutationsHIV-positive donorsHIV drug resistance mutationsViral loadMedian CD4 T-cell countCD4 T-cell percentagesHIV Organ Policy Equity (HOPE) ActCD4 T-cell countNonnucleoside reverse transcriptase inhibitorIntegrase strand transfer inhibitorsDonor-derived infectionInhibitor-based regimensT cell percentageT-cell countsHepatitis C viremiaHIV viral loadCD4 T cellsDeceased organ donorsReverse transcriptase inhibitorFalse-positive test resultsStrand transfer inhibitorsC viremiaVirologic characteristicsClinical characteristics
2020
Confronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response
Edelman EJ, Aoun-Barakat L, Villanueva M, Friedland G. Confronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response. AIDS And Behavior 2020, 24: 1977-1979. PMID: 32399798, PMCID: PMC7215127, DOI: 10.1007/s10461-020-02908-z.Peer-Reviewed Original Research
2019
Implementing Data to Care-What Are the Costs for the Health Department?
Neblett Fanfair R, Shrestha RK, Randall L, Lucas C, Nichols L, Camp NM, Brady K, Jenkins H, Altice F, Villanueva M, DeMaria A. Implementing Data to Care-What Are the Costs for the Health Department? JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82 Suppl 1: s57-s61. PMID: 31425397, DOI: 10.1097/qai.0000000000001968.Peer-Reviewed Original ResearchIntegration of care for HIV and opioid use disorder
Oldfield B, Muñoz N, McGovern M, Funaro M, Villanueva M, Tetrault J, Edelman E. Integration of care for HIV and opioid use disorder. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30882491, PMCID: PMC6588508, DOI: 10.1097/qad.0000000000002125.Peer-Reviewed Original ResearchConceptsHIV care settingsCare settingsClinical benefitTreatment settingsSystematic reviewBuprenorphine/naloxoneOpioid use disorderProvision of medicationsIntegration of careAntiretroviral therapyOpioid useMedication adherencePROSPERO databaseOvid MEDLINETreatment strategiesObservational studyHIVUse disordersModerate riskBehavioral interventionsScreening strategyOUDRisk reductionTreatmentUnique studies
2018
“No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder
Oldfield BJ, Muñoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, Tetrault JM, Edelman E. “No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. Journal Of Substance Use And Addiction Treatment 2018, 97: 28-40. PMID: 30577897, DOI: 10.1016/j.jsat.2018.11.007.Peer-Reviewed Original ResearchConceptsOpioid use disorderIntegration of HIVUse disordersClinical staffCare of HIVCommunity-based participatory research principlesBehavioral health integrationImproved patient outcomesEvidence-based treatmentsDiverse care settingsParticipatory research principlesPrimary carePatient outcomesPatient-centered policiesCare settingsHealth integrationHIVQualitative studyStages of changeClinic leadershipCare instrumentIntegrated carePatientsBehavioral healthMeasures of qualityFatal cryptococcal meningitis in an AIDS patient complicated with immune reconstitution syndrome refractory to prolonged amphotericin B treatment
Bandaranayake TD, Ogbuagu OE, Mahajan A, Vortmeyer AO, Villanueva MS. Fatal cryptococcal meningitis in an AIDS patient complicated with immune reconstitution syndrome refractory to prolonged amphotericin B treatment. International Journal Of STD & AIDS 2018, 29: 1250-1254. PMID: 29749873, DOI: 10.1177/0956462418773219.Peer-Reviewed Case Reports and Technical NotesConceptsCentral nervous system diseaseNervous system diseasesCryptococcal meningitisSystem diseasesSevere central nervous system diseaseFatal cryptococcal meningitisLiposomal amphotericin BAmphotericin B treatmentImmune recoveryPatient refractoryAntiretroviral therapyTherapeutic challengeTreatment failureAIDS patientsCystic lesionsFatal casesTreatment approachesMeningitisAmphotericin BC. neoformansMultiple coursesCryptococcus neoformansPatientsB treatmentDisease
2016
Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation
Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal Of STD & AIDS 2016, 28: 447-458. PMID: 27193421, DOI: 10.1177/0956462416651528.Peer-Reviewed Original ResearchConceptsInhibitor-based regimensRenal transplantationHIV/AIDSAntiretroviral regimenAntiretroviral therapyGraft survivalHIV-positive renal transplant recipientsEnd-stage renal diseaseHIV-positive patientsRenal transplant recipientsChronic kidney diseaseThree-year survivalInhibitor-based therapyNon-nucleoside reverseDrug-drug interactionsTransferase inhibitorsImmunosuppressive medicationsKidney transplantationTransplant recipientsAllograft rejectionGraft failureRenal diseaseCalcineurin inhibitorsClinical outcomesImmunosuppressive drugs